- Prof. Shaji Kumar
- Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Website | E-mail
Special Issue Introduction
The treatment paradigms for multiple myeloma have changed dramatically over the past few years with the introduction of novel and highly effective therapies, including monoclonal antibodies, antibody-drug conjugates, targeted small molecules, and most recently, T-cell redirection therapies including bispecific antibodies and CART. As a result of improved therapies for both newly diagnosed MM as well as relapsed disease, the survival of patients with myeloma has increased 3- to 4-fold over the past two decades. Current treatments for newly diagnosed myeloma, with or without an autologous stem cell transplantation, have resulted in deep responses that have translated to response durations exceeding five years. More recent studies have explored the development of effective four-drug regimens that have further resulted in a deeper response, including minimal residual disease negative state in a significant majority of patients, which will clearly lead to continued improvement in the survival of patients with MM. Effective salvage therapies at the time of relapse have enabled us to control the disease for prolonged periods of time, which in turn has resulted in a functional cure for some older patients with the low-risk disease even though a biological cure still remains a distant goal. Given the incurable nature of this disease, the development of new treatments with novel mechanisms of action remains the need of the hour. In addition to the therapeutic advances, major strides have been made in our understanding of the disease biology and risk stratification, bringing us closer to more individualized or risk-adapted therapy for this highly heterogeneous disease. Significant strides have been made in terms of supportive care for MM, including effective management of infections, treatment of renal failure, and prophylaxis of bone events, all of which have contributed to the progress. In this special issue, we will cover the entire spectrum of myeloma, including diagnosis and distinction from precursor phases of MGUS and smoldering myeloma, risk stratification approaches, and treatment of newly diagnosed and relapsed MM, as well as late-stage refractory disease.
Table of contents
1. Diagnosis and work up of monoclonal gammopathies
2. MGUS and smoldering myeloma
3. Risk stratification of multiple myeloma
4. Treatment of transplant eligible MM
5. Initial Treatment of transplant ineligible patients
6. Management of early relapse
7. Treatment of relapsed refractory myeloma: Immune approaches
8. Treatment of relapsed refractory myeloma: non-immune approaches
9. Supportive care management in MM
Submission Deadline30 Jun 2022